SCHEMBL1850141

SCHEMBL1850141

CC(C)(C)OC(=O)N1CCCC1C(=O)Nc1c(C(N)=O)oc2ccc(Br)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.53
LMNA P02545 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
NPC1 O15118 2/20 0.49
JAK2 O60674 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.45
KMT2A Q03164 4/20 0.45
MEN1 O00255 2/20 0.45
MAPT P10636 1/20 0.44
ALDH1A1 P00352 2/20 0.43
TSHR P16473 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
JAK3 P52333 1/20 0.41
UCHL1 P09936 1/20 0.41
RAB9A P51151 1/20 0.40
POLB P06746 1/20 0.40
FPR3 P25089 1/20 0.40
FPR2 P25090 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1851819 1.00 USP30 (0.53) USP30LMNANPSR1NPC1JAK2
SCHEMBL1851649 0.95 USP30 (0.47) USP30LMNANPSR1NPC1JAK2
SCHEMBL1854752 0.95 USP30 (0.47) USP30LMNANPSR1NPC1JAK2
SCHEMBL1855333 0.89 NPSR1 (0.49) USP30LMNANPSR1NPC1JAK2
SCHEMBL1849965 0.89 NPSR1 (0.49) USP30LMNANPSR1NPC1JAK2
SCHEMBL1851606 0.87 ALDH1A1 (0.59) USP30LMNANPSR1NPC1JAK2
SCHEMBL4115321 0.86 ALDH1A1 (0.46) LMNANPSR1NPC1KMT2AMEN1
SCHEMBL1851478 0.86 KMT2A (0.44) USP30NPSR1NPC1JAK2KMT2A
SCHEMBL1851477 0.86 KMT2A (0.44) USP30NPSR1NPC1JAK2KMT2A
SCHEMBL1859907 0.85 CYP1A2 (0.51) USP30NPSR1NPC1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
EP-2097419-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS Exelixis, Inc. (US) 2009-09-09 EP disclosed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 USP30 4459/4885LMNA 2545/4885NPSR1 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.